Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Trial details
- Registry ID
- NCT03522298
- Drugs studied
- Paxalisib (GDC-0084)
TrialRedline tracks 1 clinical trial sponsored by Kazia Therapeutics Limited: 1 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed GlioblastomaNCT03522298 | Paxalisib (GDC-0084) | Completed | 2023-03-30Actual |
Names as written in the registry records.